afatinib
Selected indexed studies
- Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. (J Thorac Oncol, 2020) [PMID:31931137]
- Afatinib. (Recent Results Cancer Res, 2018) [PMID:30069769]
- Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. (J Clin Oncol, 2025) [PMID:40239133]
_Worker-drafted node — pending editorial review._
Connections
afatinib is a side effect of
Sources
- Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. (2018) pubmed
- Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. (2020) pubmed
- Afatinib. (2018) pubmed
- Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. (2025) pubmed
- Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. (2023) pubmed
- Afatinib-induced toxic epidermal necrolysis: A case report with a literature review. (2024) pubmed
- Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. (2020) pubmed
- Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. (2021) pubmed
- Afatinib and lung cancer. (2014) pubmed
- Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review. (2023) pubmed